Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Dec;82(6):883-891.
doi: 10.1002/ana.25101. Epub 2017 Dec 8.

Natural history of infantile-onset spinal muscular atrophy

Stephen J Kolb  1   2 , Christopher S Coffey  3 , Jon W Yankey  3 , Kristin Krosschell  4 , W David Arnold  1   5 , Seward B Rutkove  6 , Kathryn J Swoboda  7   8 , Sandra P Reyna  7   9 , Ai Sakonju  7   10 , Basil T Darras  8 , Richard Shell  11 , Nancy Kuntz  12 , Diana Castro  13 , Julie Parsons  14 , Anne M Connolly  15 , Claudia A Chiriboga  16 , Craig McDonald  17 , W Bryan Burnette  18 , Klaus Werner  10 , Mathula Thangarajh  19 , Perry B Shieh  20 , Erika Finanger  21 , Merit E Cudkowicz  22 , Michelle M McGovern  22 , D Elizabeth McNeil  9   23 , Richard Finkel  24 , Susan T Iannaccone  13 , Edward Kaye  25 , Allison Kingsley  1 , Samantha R Renusch  2 , Vicki L McGovern  2 , Xueqian Wang  2 , Phillip G Zaworski  26 , Thomas W Prior  27 , Arthur H M Burghes  2 , Amy Bartlett  1 , John T Kissel  1 ; NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators  1
Affiliations
Multicenter Study

Natural history of infantile-onset spinal muscular atrophy

Stephen J Kolb et al. Ann Neurol. 2017 Dec.

Abstract

Objective: Infantile-onset spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality, typically resulting in death preceding age 2. Clinical trials in this population require an understanding of disease progression and identification of meaningful biomarkers to hasten therapeutic development and predict outcomes.

Methods: A longitudinal, multicenter, prospective natural history study enrolled 26 SMA infants and 27 control infants aged <6 months. Recruitment occurred at 14 centers over 21 months within the NINDS-sponsored NeuroNEXT (National Network for Excellence in Neuroscience Clinical Trials) Network. Infant motor function scales (Test of Infant Motor Performance Screening Items [TIMPSI], The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders, and Alberta Infant Motor Score) and putative physiological and molecular biomarkers were assessed preceding age 6 months and at 6, 9, 12, 18, and 24 months with progression, correlations between motor function and biomarkers, and hazard ratios analyzed.

Results: Motor function scores (MFS) and compound muscle action potential (CMAP) decreased rapidly in SMA infants, whereas MFS in all healthy infants rapidly increased. Correlations were identified between TIMPSI and CMAP in SMA infants. TIMPSI at first study visit was associated with risk of combined endpoint of death or permanent invasive ventilation in SMA infants. Post-hoc analysis of survival to combined endpoint in SMA infants with 2 copies of SMN2 indicated a median age of 8 months at death (95% confidence interval, 6, 17).

Interpretation: These data of SMA and control outcome measures delineates meaningful change in clinical trials in infantile-onset SMA. The power and utility of NeuroNEXT to provide "real-world," prospective natural history data sets to accelerate public and private drug development programs for rare disease is demonstrated. Ann Neurol 2017;82:883-891.

PubMed Disclaimer

Conflict of interest statement

Potential Conflicts of Interest:

The authors have nothing to report.

Figures

Figure 1
Figure 1. Retention in SMA cohort
Age of infants at the time of death (filled circle), completion of the study (filled square) or loss to follow up (censored event, open circle). Age of scheduled study visits denoted on the x axis. Approximate age of permanent endotracheal intubation for respiratory support (closed triangle) is denoted for two infants. Bar colors denote SMN2 copy number; 4 copies = Grey, 3 copies = Blue, 2 copies = Red, Unknown copies = White.
Figure 2
Figure 2. Progression of Outcomes
Longitudinal average weight and motor function test results in first two years of life for healthy infants (blue), SMA infants where SMN2 copy number = 2 or is unknown (red) and SMA infants where SMN2 copy number > 2 (grey). A) Average weight in kilograms at each study visit. B) Average Test of Infant Motor Performance Screening Items (TIMPSI) score, C) The Children’s Hospital of Philadelphia Infant Test for Neuromuscular Disorders (CHOP-INTEND) score and D) Alberta Infant Motor Score (AIMS) score at each study visit. E) Average ulnar CMAP peak area (mV/s). Study visits linked to infant age (in months, +/− 2 weeks for visits 6, 12, 18 and 24 months). Shaded areas describe the standard deviation for each mean at each study visit. F) Kaplan-Meier curve of time to death or endotracheal tube placement plotted separately for the subgroup of SMA infants with SMN2 copy number equal to 3 or 4 (solid red line, n = 6) and for the subgroup of SMA infants with SMN2 copy number equal to 2 or unknown (dashed red line, n = 20). Circles represent censored events that occurred when participants left the study before observing either event in the combined endpoint.
Figure 3
Figure 3. Change in CHOP-INTEND in SMA Infants
Change in CHOP-INTEND score from the score obtained on the 6-month study visit for each infant in the SMA cohort (black lines). A mixed effects model was fit to model change for each time period and was adjusted for the 6-month CHOP-INTEND score (red line). Dashed black lines denote infants who received invasive ventilatory support. All differences in CHOP-INTEND from 6-months on were statistically significant. A test for linear trend was performed using orthogonal polynomials and the observed trend in differences was not linear (p = 0.1161).
See this image and copyright information in PMC

Comment in

Similar articles

  • Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study.
    Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AH, Bartlett A, Kissel JT; NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators. Kolb SJ, et al. Ann Clin Transl Neurol. 2016 Jan 21;3(2):132-45. doi: 10.1002/acn3.283. eCollection 2016 Feb. Ann Clin Transl Neurol. 2016. PMID: 26900585 Free PMC article.
  • Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study.
    Krosschell KJ, Bosch M, Nelson L, Duong T, Lowes LP, Alfano LN, Benjamin D, Carry TB, Devine G, Kelley C, Gadekan R, Malkus EC, Pasternak A, Provance-Orr S, Roemeiser-Logan L, Nicorici A, Trussell D, Young SD, Fetterman JR, Montes J, Powers PJ, Quinones R, Quigley J, Coffey CS, Yankey JW, Bartlett A, Kissel JT, Kolb SJ; NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators. Krosschell KJ, et al. J Neuromuscul Dis. 2018;5(4):509-521. doi: 10.3233/JND-180327. J Neuromuscul Dis. 2018. PMID: 30223401 Free PMC article.
  • Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
    Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, Iannaccone ST, Kuntz NL, Peña LDM, Shieh PB, Smith EC, Kwon JM, Zaidman CM, Schultz M, Feltner DE, Tauscher-Wisniewski S, Ouyang H, Chand DH, Sproule DM, Macek TA, Mendell JR. Day JW, et al. Lancet Neurol. 2021 Apr;20(4):284-293. doi: 10.1016/S1474-4422(21)00001-6. Epub 2021 Mar 17. Lancet Neurol. 2021. PMID: 33743238 Clinical Trial.
  • [Spinal muscular atrophy : Time for newborn screening?].
    Vill K, Blaschek A, Schara U, Kölbel H, Hohenfellner K, Harms E, Olgemöller B, Walter MC, Müller-Felber W. Vill K, et al. Nervenarzt. 2017 Dec;88(12):1358-1366. doi: 10.1007/s00115-017-0447-3. Nervenarzt. 2017. PMID: 29101527 Review. German.
  • Spinal muscular atrophy: a time for screening.
    Prior TW. Prior TW. Curr Opin Pediatr. 2010 Dec;22(6):696-702. doi: 10.1097/MOP.0b013e32833f3046. Curr Opin Pediatr. 2010. PMID: 20829691 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pearn JH. The gene frequency of acute Werdnig-Hoffmann disease (SMA type 1). A total population survey in North-East England. Journal of medical genetics. 1973;10(3):260–5. - PMC - PubMed
    1. Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. European journal of human genetics : EJHG. 2012;20(1):27–32. - PMC - PubMed
    1. Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Archives of neurology. 1995;52(5):518–23. - PubMed
    1. Munsat T, Davies K. Spinal muscular atrophy. 32nd ENMC International Workshop. Naarden, The Netherlands, 10–12 March 1995. Neuromuscular disorders : NMD. 1996;6(2):125–7. - PubMed
    1. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nature genetics. 1997;16(3):265–9. - PubMed

Publication types

MeSH terms